Scroll to top
- Follow Us
- –

̍̍ CSE: BRAX
̍̍ OTC: BRAXF
̍̍ FWB: 4960

©2022 Braxia Scientific Corp.

DISCLAIMER — The information on this site should not be used to make decisions about medical treatments. Please conduct your own research and due diligence before making any major health changes. Braxia Scientific, its members, directors, employees, and representatives are not responsible for damages of any nature arising out of or relating to the use of this website or any hyperlinked websites. The material that appears on this website is for informational purposes only. Braxia Scientific has made every effort to provide useful and accurate information. However, errors may appear from time to time. Braxia Scientific and its information providers make no warranty as to the reliability, timeliness, completeness, accuracy or usefulness of the information on the website. Any opinion, view, or idea contained in an article, story or column published on this website is that of the author and does not reflect or represent the views of Braxia Scientific or any of its members, directors, employees and representatives.

Go back

Events News Releases

4 min read

ENROLLMENT FOR SEPTEMBER 2021

Published on June 23, 2021

Home
Events
ENROLLMENT FOR SEPTEMBER 2021

BRAXIA INSTITUTE TRAINING PROGRAM ENROLLMENT FOR SEPTEMBER 2021

Braxia Institute Psilocybin-Assisted Therapy Training Program

Request for Applications for Class of 2022

A total of 14 qualified therapists will be selected for the training program. The training program will include didactic teaching, peer teaching, group discussion and simulations followed by a practicum component. The practicum component will include administering psilocybin-assisted therapy for participants with depression as part of a Health Canada approved clinical trial. We hope to recruit an interdisciplinary group of physicians, psychologists and psychotherapists. Therapists will work in dyads, pairing physician therapists with non-physician therapists as at least one physician is required for all psilocybin doses administered. You will receive group peer-supervision throughout the program. The goal of the course is to become fully competent to perform psilocybin-assisted therapy for future clinical trials and possibly clinical care, if psilocybin is approved by Health Canada in the future.

NOTE: Applications for this year’s program are currently closed
Application Deadline: July 11, 2021
Tentative Program Start Date: September 2021 (pandemic permitting)

Click here for more information

Symbols – CSE: BRAX OTC: BRAXF FWB: 496

Tagged with: cohortENROLLMENTtraining program

Next Post

WEBCAST ALERT: H.C. WAINWRIGHT & CO.

Events News Releases

Graduates First Cohort of Medical Professionals

Braxia Scientific Graduates First Cohort of Medical Professionals From Psilocybin-Assisted Therapy Training Program; Ready to Start Health Canada Approved Psilocybin Clinical Trial TORONTO, ONTARIO November 2, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is excited to announce the completion of the training program for psilocybin-assisted clinical therapy by its first multi-disciplinary cohort of 20 qualified therapists from diverse psychiatry and psychotherapy backgrounds. This program was implemented by the Braxia Institute, the Company’s training centre focused on advancing psychiatric clinical practice and health services of ketamine and psychedelic treatment therapy. Through this program, the Company is able to develop, train, and support qualified, independent medical physicians, psychologists and psychotherapists skilled in best practices to implement safe and...

BRAXIA SCIENTIFIC LAUNCHES PSILOCYBIN-ASSISTED CLINICAL THERAPY TRAINING PROGRAM

BRAXIA SCIENTIFIC LAUNCHES PSILOCYBIN-ASSISTED CLINICAL THERAPY TRAINING PROGRAM TO DEVELOP NEW GENERATION OF QUALIFIED PHYSICIANS, PSYCHOTHERAPISTS AND PSYCHOLOGISTS FOR MENTAL HEALTH TORONTO, ONTARIO June 29, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing novel ketamine treatments for persons with depression and related disorders, is pleased to announce it has launched its psilocybin-assisted clinical therapy training program. Through this program, Braxia will develop, train and support a new generation of qualified, skilled in best practices independent medical physicians, psychologists and psychotherapists to implement safe and effective psilocybin-assisted therapy for patients with depression. The therapists will participate in the provision of psychotherapy in upcoming clinical trials at Braxia evaluating the safety and efficacy of psilocybin in depression. The Company anticipates that, pending regulatory approval of psilocybin, therapists would also be...